바토클리맙

Batoclimab
바토클리맙
단일클론항체
유형?
식별자
CAS 번호
유니아이

바토클리맙(Batoclimab, HBM9161 또는 HL161)은 피하 주사에 의해 투여되는 완전 인간 단일클론항체입니다. 신생아 단편 결정화 수용체를 억제하여 티로트로핀 수용체의 항체 감소를 유도합니다. 근육통과 갑상선 눈 질환을 치료하기 위해 개발 중입니다.[1][2][3]

참고문헌

  1. ^ Kahaly, George J.; Dolman, Peter J.; Wolf, Jan; Giers, Bert C.; Elflein, Heike M.; Jain, Amy P.; Srinivasan, Ashok; Hadjiiski, Lubomir; Jordan, David; Bradley, Elizabeth A.; Stan, Marius N.; Eckstein, Anja; Pitz, Susanne; Vorländer, Christian; Wester, Sara T.; Nguyen, John; Tucker, Nancy; Sales-Sanz, Marco; Feldon, Steven E.; Nelson, Christine C.; Hardy, Isabelle; Abia-Serrano, Maravillas; Tedeschi, Philip; Janes, Jonathan M.; Xu, Jing; Vue, Peter; Macias, William L.; Douglas, Raymond S. (30 June 2023). "Proof-of-Concept and Randomized, Placebo-Controlled Trials of an Fcrn Inhibitor, Batoclimab, for Thyroid Eye Disease". The Journal of Clinical Endocrinology and Metabolism. 108 (12): 3122–3134. doi:10.1210/clinem/dgad381. ISSN 1945-7197. PMID 37390454. S2CID 259303423.
  2. ^ Yan, Chong; Duan, Rui-Sheng; Yang, Huan; Li, Hai-Feng; Zou, Zhangyu; Zhang, Hua; Zhou, Hongyu; Li, Xiao-Li; Zhou, Hao; Jiao, Lidong; Chen, Jialin; Yin, Jian; Du, Qin; Lee, Michael; Chen, Yu; Chen, Xiaoxiang; Zhao, Chongbo (June 2022). "Therapeutic Effects of Batoclimab in Chinese Patients with Generalized Myasthenia Gravis: A Double-Blinded, Randomized, Placebo-Controlled Phase II Study". Neurology and Therapy. 11 (2): 815–834. doi:10.1007/s40120-022-00345-9. PMC 9095773. PMID 35412216.
  3. ^ Yap, Desmond Y. H.; Hai, Jojo; Lee, Paul C. H.; Zhou, Xueying; Lee, Michael; Zhang, Yu; Wang, Meng; Chen, Xiaoxiang (September 2021). "Safety, tolerability, pharmacokinetics, and pharmacodynamics of HBM9161, a novel FcRn inhibitor, in a phase I study for healthy Chinese volunteers". Clinical and Translational Science. 14 (5): 1769–1779. doi:10.1111/cts.13019. PMC 8504844. PMID 33742786.